| Bioactivity | Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration and can be used for the research of spinal cord injury[1]. |
| Target | RGMa |
| Name | Unasnemab |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Saori Obayashi. Phase 2 Trial of MT-3921 initiated for treatment of spinal cord injury. |